Composition of Total Revenue (Tables)

12 Months Ended

Dec. 31, 2016

Segment Reporting [Abstract]

Schedule of Net Product Sales by Geography

The below table presents our net product sales by geography for the years ended December 31, 2016, 2015, and 2014:

	Year Ended December 31,
	2016				2015				2014
United States	$	125,074	97.3	%	$	130,432	95.3	%	$	177,979	95.4	%
International:
Europe	3,522		2.7	%	2,234		1.6	%	3,357		1.8	%
Asia Pacific*	—		—	%	4,185		3.1	%	5,201		2.8	%
Total International	3,522		2.7	%	6,419		4.7	%	8,558		4.6	%
Net product sales	$	128,596	100	%	$	136,851	100.0	%	$	186,537	100.0	%

* See Note 12 for discussion of our November 2015 out-license for the Asia Pacific territory to Mundipharma

Schedule of Net Product Sales by Product Line

The below table presents our net product sales by drug for the years ended December 31, 2016, 2015, and 2014:

	Year Ended December 31,
	2016				2015				2014
FUSILEV	$	34,839	27.1	%	$	60,710	44.4	%	$	105,608	56.6	%
FOLOTYN	46,245		36.0	%	40,606		29.7	%	47,556		25.5	%
ZEVALIN	10,730		8.3	%	17,457		12.8	%	22,169		11.9	%
MARQIBO	7,245		5.6	%	8,006		5.9	%	6,328		3.4	%
BELEODAQ	13,368		10.4	%	10,072		7.4	%	4,876		2.6	%
EVOMELA	16,169		12.6	%	—		—	%	—		—	%
Net product sales	$	128,596	100.0	%	$	136,851	100.0	%	$	186,537	100.0	%

Summary of Customers Representing 10% or More of Gross Product Sales

The below table presents the customers that represent 10% or more of our gross product sales in 2016, 2015, and 2014:

	Year Ended December 31,
	2016				2015				2014
AmerisourceBergen Corporation, and its affiliates	$	93,951	38.4	%	$	78,989	36.7	%	$	115,079	40.4	%
McKesson Corporation and its affiliates	75,952		31.0	%	73,577		34.2	%	93,656		32.9	%
Cardinal Health, Inc. and its affiliates	58,780		24.0	%	37,414		17.4	%	*		—	%
All other customers	16,087		6.6	%	25,156		11.7	%	75,950		26.7	%
Gross product sales	$	244,770	100.0	%	$	215,136	100.0	%	$	284,685	100.0	%

* Less than 10%

The below table presents our license fees and service revenue by source for the years ended December 31, 2016, 2015, and 2014:

	Year Ended December 31,
	2016				2015				2014
Out-license of ZEVALIN, FOLOTYN, BELEODAQ, MARQIBO: upfront receipt for the Canada territory (Note 17(b)(xiv))	$	6,000	33.6	%	$	—	—	%	$	—	—	%
Sales and marketing contracted services (Note 14)	9,096		51.0	%	—		—	%	—		—	%
Out-license of ZEVALIN: upfront receipts and royalties for Asia and certain other territories, excluding China (Note 12)	1,756		9.8	%	15,144		58.9	%	—		—	%
Out-license of FOLOTYN in all countries except the U.S., Canada, Europe, and Turkey (Note 16)	927		5.2	%	831		3.2	%	293		100.0	%
Out-license of ZEVALIN, MARQIBO, EVOMELA: upfront receipt for the China territory (Note 11)	—		—	%	9,682		37.7	%	—		—	%
Out-license of ZEVALIN: amortization of upfront receipt related to India territory (Note17(b)(iii)) and other	69		0.4	%	48		0.2	%	—		—	%
License fees and service revenues	$	17,848	100.0	%	$	25,705	100.0	%	$	293	100.0	%